Skip to main content Skip to journal navigation menu Skip to site footer
contact@ukscip.com
Article

The Influence of Nanoparticles of Graphene Oxide‑PEG on Cytokine Profile of Monocytes from Human Blood In Vitro

Usanina D.I. ORCID ,  Bochkova M.S. ORCID ,  Timganova V.P. ORCID ,  Shardina K.Yu ORCID ,  Zamorina S.A. ORCID ,  Rayev M.B. ORCID

    Received: 25 November 2024; Revised: 3 January 2025; Accepted: 6 January 2025; Published: 17 January 2025

    Abstract

    This study investigated the response of human monocytes to co-culture with pegylated (linear or branched) graphene oxide (GO) nanoparticles, specifically examing both small (P-GOs, 100 -200 nm) and larger (P-GOb, 1-5 μm) particles at concentrations of 5, 25, and 50 µg mL–1. Human monocytes (CD14+ cells) were isolated and cultured with these nanoparticles for 72 hours. We measured cell viability, lactate dehydrogenase (LDH) release, and cytokine production. The findings showed that P-GO nanoparticles had little effect on  cytokine production, including MIF, GM-CSF, VEGF, IP-10, IL-8, HGF, and SCGF-beta in vitro. At a low concentration (5 μg mL–1),  P-GO exhibited minimal influence on cytokines, except forthe LP-GOb variant, which increased M-CSF production. Conversely, 25 and 50 μg mL–1 of P-GO nanoparticles enhanced the release of variouscytokines, including proinflammatory IL-6, IL-1β, IL-1α, IL-18, IL-17, IL-16, IFN-γ, TNF-β, TNF-α, anti-inflammatory IL-1ra, IL-13, IL-10, IL-4, regulatory  G-CSF, IL-2, IL-3, IL-5, IL-12 (p40), IL-12 (p70), M-CSF, GM-CSF and chemokines CTACK, Eotaxin, GRO-α, RANTES, MIP-1β, MCP-1, MIP-1α, MCP-3, MIG, SDF-1α, growth factors Basic FGF, PDGF-BB, SCF, and LIF and TRAIL. Although higher concentrations of P-GO nanoparticles resulted in significant cytokine production, monocyte viability remained largely unaffected . LDH release was elevated solely in samples treated with 50 μg mL–1 of LP-GOb. BP-GOs showed minimal influence on cytokine profiles, raising M-CSF levels at the highest concentration. These results indicate that modifying graphene oxide nanoparticles may hold potential for creating graphene-based pharmacological agents.

    Keywords

    References

    1. 1. Pandit, S.; Gaska, K.; Kádár, R.; et al. Graphene-Based Antimicrobial Biomedical Surfaces. Chemphyschem 2021, 22, 250–263. DOI: https://doi.org/10.1002/cphc.202000769
    2. 2. Svadlakova, T.; Holmannova, D.; Kolackova, M.; et al. Immunotoxicity of Carbon-Based Nanomaterials, Starring Phagocytes. Int. J. Mol. Sci. 2022, 23, 8889. DOI: https://doi.org/10.3390/ijms23168889
    3. 3. Wang, H.; Gu, W.; Xiao, N.; et al. Chlorotoxin-Conjugated Graphene Oxide for Targeted Delivery of an Anticancer Drug. Int. J. Nanomed. 2014, 9, 1433–1442. DOI: https://doi.org/10.2147/IJN.S58783
    4. 4. Zhang, Y.; Nayak, T.R.; Hong, H.; et al. Graphene: A Versatile Nanoplatform for Biomedical Applications. Nanoscale 2012, 4, 3833–3842. DOI: https://doi.org/10.1039/c2nr31040f
    5. 5. Kim, J.; Park, S.J.; Min, D.H. Emerging Approaches for Graphene Oxide Biosensor. Anal. Chem. 2017, 89, 232–248. DOI: https://doi.org/10.1021/acs.analchem.6b04248
    6. 6. Lin. J.; Chen, X.; Huang, P. Graphene-Based Nanomaterials for Bioimaging. Adv. Drug Deliv. Rev. 2016, 105, 242–254. DOI: https://doi.org/10.1016/j.addr.2016.05.013
    7. 7. Asadi, M.; Ghorbani, S.H.; Mahdavian, L.; et al. Graphene-Based Hybrid Composites for Cancer Diagnostic and Therapy. J. Transl. Med. 2024, 22, 611. DOI: https://doi.org/10.1186/s12967-024-05438-7
    8. 8. Hoseini-Ghahfarokhi, M.; Mirkiani, S.; Mozaffari, N.; et al. Applications of Graphene and Graphene Oxide in Smart Drug/Gene Delivery: Is the World Still Flat? Int. J. Nanomed. 2020, 15, 9469–9496. DOI: https://doi.org/10.2147/IJN.S265876
    9. 9. Park, E.J.; Lee, S.J.; Lee, K.; et al. Pulmonary Persistence of Graphene Nanoplatelets May Disturb Physiological and Immunological Homeostasis. J. Appl. Toxicol. 2017, 37, 296–309. DOI: https://doi.org/10.1002/jat.3361
    10. 10. Gustafson, H.H.; Holt-Casper, D.; Grainger, D.W.; et al. Nanoparticle Uptake: The Phagocyte Problem. Nano Today 2015, 10, 487–510. DOI: https://doi.org/10.1016/j.nantod.2015.06.006
    11. 11. Makharza, S.; Cirillo, G.; Bachmatiuk, A.; et al. Graphene Oxide-Based Drug Delivery Vehicles: Functionalization, Characterization, and Cytotoxicity Evaluation. J. Nanopart. Res. 2013, 15, 2099. DOI: https://doi.org/10.1007/s11051-013-2099-y
    12. 12. Singh, D.P.; Herrera, C.E.; Singh, B.; et al. Graphene Oxide: An Efficient Material and Recent Approach for Biotechnological and Biomedical Applications. Mater. Sci. Eng. C Mater. Biol. Appl. 2018, 86, 173–197. DOI: https://doi.org/10.1016/j.msec.2018.01.004
    13. 13. Khramtsov, P.; Bochkova, M.; Timganova, V.; et al. Interaction of Graphene Oxide Modified with Linear and Branched PEG with Monocytes Isolated from Human Blood. Nanomaterials 2021, 12, 126. DOI: https://doi.org/10.3390/nano12010126
    14. 14. Uzhviyuk, S.; Bochkova, M.; Timganova, V.; et al. PEGylated Graphene Oxide and Monocyte Metabolism. AIP Conf. Proc. 2024, 2924, 050005. DOI: https://doi.org/10.1063/5.0182629
    15. 15. Mukherjee, S.P.; Bottini, M.; Fadeel, B. Graphene and the Immune System: A Romance of Many Dimensions. Front. Immunol. 2017, 8, 673. DOI: https://doi.org/10.3389/fimmu.2017.00673
    16. 16. Tang, J.; Cheng, W.; Gao, J.; et al. Occupational Exposure to Carbon Black Nanoparticles Increases Inflammatory Vascular Disease Risk: An Implication of an ex Vivo Biosensor Assay. Part. Fibre Toxicol. 2020, 17. DOI: https://doi.org/10.1186/s12989-020-00378-8
    17. 17. Di Ianni, E.; Møller, P.; Vogel, U.B.; et al. Pro-Inflammatory Response and Genotoxicity Caused by Clay and Graphene Nanomaterials in A549 and THP-1 Cells. Mutat. Res. Genet. Toxicol. Environ. Mutagen. 2021, 872, 503405. DOI: https://doi.org/10.1016/j.mrgentox.2021.503405
    18. 18. Kinaret, P.A.S.; Scala, G.; Federico, A.; et al. Carbon Nanomaterials Promote M1/M2 Macrophage Activation. Small 2020, 16, 1907609. DOI: https://doi.org/10.1002/smll.201907609
    19. 19. Aventaggiato, M.; Valentini, F.; Caissutti, D.; et al. Biological Effects of Small Sized Graphene Oxide Nanosheets on Human Leukocytes. Biomedicines 2024, 12, 256. DOI: https://doi.org/10.3390/biomedicines12020256
    20. 20. Cebadero-Dominguez, Ó.; Casas-Rodríguez, A.; Puerto, M.; et al. In Vitro Safety Assessment of Reduced Graphene Oxide in Human Monocytes and T Cells. Environ. Res. 2023, 232, 116356. DOI: https://doi.org/10.1016/j.envres.2023.116356
    21. 21. Yan, J.; Chen, L.; Huang, C.C.; et al. Consecutive Evaluation of Graphene Oxide and Reduced Graphene Oxide Nanoplatelets Immunotoxicity on Monocytes. Colloids Surf. B. Biointerfaces. 2017, 153, 300–309. DOI: https://doi.org/10.1016/j.colsurfb.2017.02.036
    22. 22. Longhin, E.M.; El Yamani, N.; Rundén-Pran, E.; et al. The Alamar Blue Assay in the Context of Safety Testing of Nanomaterials. Front. Toxicol. 2022, 4, 981701. DOI: https://doi.org/10.3389/ftox.2022.981701
    23. 23. Feng, Y.; Xiong, Y.; Qiao, T.; et al. Lactate Dehydrogenase A: A Key Player in Carcinogenesis and Potential Target in Cancer Therapy. Cancer Med. 2018, 7, 6124–6136. DOI: https://doi.org/10.1002/cam4.1820
    24. 24. Kregielewski, K.; Fraczek, W.; Grodzik, M. Graphene Oxide Enhanced Cisplatin Cytotoxic Effect in Glioblastoma and Cervical Cancer. Molecules 2023, 28, 6253. DOI: https://doi.org/10.3390/molecules28176253
    25. 25. Yan, L.; Wang, Y.; Xu, X.; et al. Can Graphene Oxide Cause Damage to Eyesight? Chem. Res. Toxicol. 2012, 25, 1265–1270. DOI: https://doi.org/10.1021/tx300129f
    26. 26. Wójcik, B.; Zawadzka, K.; Sawosz, E.; et al. Cell Line-Dependent Adhesion and Inhibition of Proliferation on Carbon-Based Nanofilms. Nanotechnol. Sci. Appl. 2023, 16, 41–57. DOI: https://doi.org/10.2147/NSA.S439185
    27. 27. Gurunathan, S.; Kang, M.H.; Jeyaraj, M.; et al. Differential Cytotoxicity of Different Sizes of Graphene Oxide Nanoparticles in Leydig (TM3) and Sertoli (TM4) Cells. Nanomaterials 2019, 9, 139. DOI: https://doi.org/10.3390/nano9020139
    28. 28. Choi, Y.J.; Kim, E.; Han, J.; et al. A Novel Biomolecule-Mediated Reduction of Graphene Oxide: A Multifunctional Anti-Cancer Agent. Molecules 2016, 21, 375. DOI: https://doi.org/10.3390/molecules21030375
    29. 29. Gurunathan, S.; Kang, M.H.; Jeyaraj, M.; et al. Differential Immunomodulatory Effect of Graphene Oxide and Vanillin-Functionalized Graphene Oxide Nanoparticles in Human Acute Monocytic Leukemia Cell Line (THP-1). Int. J. Mol. Sci. 2019, 20, 247. DOI: https://doi.org/10.3390/ijms20020247
    30. 30. Gurunathan, S.; Arsalan Iqbal, M.; Qasim, M.; et al. Evaluation of Graphene Oxide Induced Cellular Toxicity and Transcriptome Analysis in Human Embryonic Kidney Cells. Nanomaterials 2019, 9, 969. DOI: https://doi.org/10.3390/nano9070969
    31. 31. Zhang, J.; Cao, H.Y.; Wang, J.Q.; et al. Graphene Oxide and Reduced Graphene Oxide Exhibit Cardiotoxicity Through the Regulation of Lipid Peroxidation, Oxidative Stress, and Mitochondrial Dysfunction. Front. Cell Dev. Biol. 2021, 9, 616888. DOI: https://doi.org/10.3389/fcell.2021.616888
    32. 32. Chen, W.; Wang, B.; Liang, S.; et al. Understanding the Role of the Lateral Dimensional Property of Graphene Oxide on Its Interactions with Renal Cells. Molecules 2022, 27, 7956. DOI: https://doi.org/10.3390/molecules27227956
    33. 33. Ma, Y.; Wang, J.; Wu, J.; et al. Meta-Analysis of Cellular Toxicity for Graphene via Data-Mining the Literature and Machine Learning. Sci. Total Environ. 2021, 793, 148532. DOI: https://doi.org/10.1016/j.scitotenv.2021.148532
    34. 34. Farrera, C., Fadeel, B. It Takes Two to Tango: Understanding the Interactions between Engineered Nanomaterials and the Immune system. Eur. J. Pharm. Biopharm. 2015, 95, 3–12. DOI: https://doi.org/10.1016/j.ejpb.2015.03.007
    35. 35. Luo, N.; Weber, J.K.; Wang, S.; et al. PEGylated Graphene Oxide Elicits Strong Immunological Responses despite Surface Passivation. Nat. Commun. 2017, 8, 14537. DOI: https://doi.org/10.1038/ncomms14537
    36. 36. Fusco, L.; Avitabile, E.; Armuzza, V.; et al. Impact of the surface functionalization on nanodiamond biocompatibility: A comprehensive view on human blood immune cells. Carbon. 2020, 160, 390–404. DOI: https://doi.org/10.1016/j.carbon.2020.01.003
    37. 37. Knötigová, P.T.; Mašek, J.; Hubatka, F.; et al. Application of Advanced Microscopic Methods to Study the Interaction of Carboxylated Fluorescent Nanodiamonds with Membrane Structures in THP-1 Cells: Activation of Inflammasome NLRP3 as the Result of Lysosome Destabilization. Mol. Pharm. 2019, 16, 3441–3451. DOI: https://doi.org/10.1021/acs.molpharmaceut.9b00225
    38. 38. Kong, C.; Chen, J.; Li, P.; et al. Respiratory Toxicology of Graphene-Based Nanomaterials: A Review. Toxics 2024, 12, 82. DOI: https://doi.org/10.3390/toxics12010082
    39. 39. Fajgenbaum, D.C.; June, C.H. Cytokine Storm. N. Engl. J. Med. 2020, 383(23), 2255–2273. DOI: https://doi.org/10.1056/NEJMra2026131
    40. 40. Vallhov, H.; Qin, J.; Johansson, S.M.; et al. The Importance of an Endotoxin-Free Environment during the Production of Nanoparticles Used in Medical Applications. Nano Lett. 2006, 6, 1682–1686. DOI: https://doi.org/10.1021/nl060860z
    41. 41. Oostingh, G.J.; Casals, E.; Italiani, P.; et al. Problems and Challenges in the Development and Validation of Human Cell-Based Assays to Determine Nanoparticle-Induced Immunomodulatory Effects. Part. Fibre Toxicol. 2011, 8, 8. DOI: https://doi.org/10.1186/1743-8977-8-8
    42. 42. Mukherjee, S.P.; Kostarelos, K.; Fadeel, B. Cytokine Profiling of Primary Human Macrophages Exposed to Endotoxin-Free Graphene Oxide: Size-Independent NLRP3 Inflammasome Activation. Adv. Healthc. Mater. 2018, 7, 1700815. DOI: https://doi.org/10.1002/adhm.201700815
    43. 43. Orecchioni, M.; Bedognetti, D.; Newman, L.; et al. Single-Cell Mass Cytometry and Transcriptome Profiling Reveal the Impact of Graphene on Human Immune Cells. Nat. Commun. 2017, 8, 1109. DOI: https://doi.org/10.1038/s41467-017-01015-3
    ×